- Home
- INTS
INTS
Intensity Therapeutics Inc. Common stock
as 01-22-2025 4:00pm EST
| Founded: | 2012 | Country: | United States |
| Employees: | N/A | City: | SHELTON |
| Market Cap: | N/A | IPO Year: | 2023 |
| Target Price: | $8.50 | AVG Volume (30 days): | 49.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.18 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.50 - $5.94 | Next Earning Date: | 03-13-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Intensity Therapeutics Inc. Common stock News
INTS Breaking Stock News: Dive into INTS Ticker-Specific Updates for Smart Investing
PR Newswire
13 days ago
Intensity Therapeutics Provides Business Update Highlighting Key Achievements with Lead Drug Candidate INT230-6
MT Newswires
a month ago
Intensity Therapeutics Says Stockholder Armistice Capital May Sell 1.24 Million Shares
TipRanks
a month ago
Intensity Therapeutics reports positive results of INT230-6 in breast cancer
MT Newswires
a month ago
Intensity Therapeutics Says Cancer Drug Candidate Shows Benefits in Phase 2 Trial
PR Newswire
a month ago
Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Present Phase 2 Data in Presurgical Breast Cancer from the completed INVINCIBLE-2 Study, and an Overview of the Ongoing Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial, INVINCIBLE-4 (SAKK 66/22), at the 2024 San Antonio Breast Cancer Symposium (SABCS)
PR Newswire
2 months ago
Intensity Therapeutics, Inc. Announces Pricing of $3 Million Registered Direct Offering and Concurrent Private Placement
PR Newswire
2 months ago
Intensity Therapeutics Presents INT230-6 Phase 1/2 Data in Sarcoma and an Overview of its Ongoing Global Randomized Phase 3 Sarcoma Trial ("INVINCIBLE-3 Study") in a Late-Breaking Session at the 2024 Annual Connective Tissue Oncology Society Meeting (CTOS)
PR Newswire
2 months ago
Intensity Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Compare INTS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "INTS Intensity Therapeutics Inc. Common stock - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.